P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma (Q39174795)

9 September 2017

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma (English)

1 reference

9 September 2017

11

1 reference

9 September 2017

Christy C Ong

1

1 reference

9 September 2017

Adrian M Jubb

2

1 reference

9 September 2017

Diana Jakubiak

3

1 reference

9 September 2017

Wei Zhou

4

1 reference

9 September 2017

Joachim Rudolph

5

1 reference

9 September 2017

Peter M Haverty

6

1 reference

9 September 2017

Marcin Kowanetz

7

1 reference

9 September 2017

Yibing Yan

8

1 reference

9 September 2017

Jarrod Tremayne

9

1 reference

9 September 2017

Richard Lisle

10

1 reference

9 September 2017

Lori S Friedman

12

1 reference

9 September 2017

Marcia Belvin

13

1 reference

9 September 2017

Mark R Middleton

14

1 reference

9 September 2017

Elizabeth M Blackwood

15

1 reference

9 September 2017

Hartmut Koeppen

16

1 reference

9 September 2017

Klaus P Hoeflich

17

1 reference

9 September 2017

language of work or name

English

0 references

publication date

27 March 2013

1 reference

Journal of the National Cancer Institute

9 September 2017

1 reference

9 September 2017

105

1 reference

9 September 2017

9

1 reference

9 September 2017

606-607

1 reference

The role of mitogen- and stress-activated protein kinase pathways in melanoma

9 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

BRAF targeted therapy changes the treatment paradigm in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. insights into mechanisms of Raf-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

p21-activated kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

p21-activated kinase 1: PAK'ed with potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Design and analysis of dose-finding studies combining multiple comparisons and modeling procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

A FOXO-Pak1 transcriptional pathway controls neuronal polarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

LAT-independent Erk activation via Bam32-PLC-γ1-Pak1 complexes: GTPase-independent Pak1 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Mutant BRAF melanomas--dependence and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT054

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT054

1 reference

9 September 2017

1 reference